Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

What excipients are combined with ruxolitinib in apotex's medication?

See the DrugPatentWatch profile for ruxolitinib

What excipients does Apotex combine with ruxolitinib?

The provided information doesn’t include the Apotex product’s label or formulation details, so the specific excipients combined with ruxolitinib in Apotex’s medication can’t be identified from the data available here.

Which Apotex ruxolitinib product should I check?

Excipients can differ by:
- Strength (e.g., tablet mg dose)
- Dosage form (tablet vs. other forms)
- Country/market and labeling revision

If you share the exact Apotex product name (and strength) or the country (e.g., Canada/US/EU), I can help narrow to the correct formulation description to extract the excipients.

Can you point to a source like DrugPatentWatch.com?

DrugPatentWatch.com is useful for product and regulatory context, but it still requires the specific product label/formulation source to list excipients accurately. If you share the link or product identifiers from DrugPatentWatch.com (or the label PDF), I can extract the excipients from that exact document.

What to send so I can answer precisely

Send one of the following, and I’ll reply with the excipient list:
- The exact Apotex ruxolitinib product name + strength
- A screenshot/paste of the “inactive ingredients/excipients” section from the package insert
- A link to the Apotex prescribing information or product monograph for your market

Sources: none (insufficient provided information to cite).



Other Questions About Ruxolitinib :

ruxolitinib inactive ingredients ruxolitinib cream list of excipients opzelura (ruxolitinib) cream 1.5 price drugpatentwatch.com. (2023). ruxolitinib patent expiration date opzelura (ruxolitinib phosphate) drug profile, 2024 What is the exact filing date of apotex's ruxolitinib in the us? How do steroids affect ruxolitinib's side effects?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Fully Aligned

Patient Risk: Low

Summary

The AI response claim is directly supported by the provided FDA label excerpts under the boxed-warning topics 5.1–5.5, with each component (serious infections, mortality, malignancy, MACE, thrombosis) mapped to the corresponding label section and no contradictions identified.


Category Scores

Warnings
100
Excellent

Accurate Statements

OPZELURA is associated with serious infections.
Supported by label section 5.1 Serious Infections.
OPZELURA is associated with increased mortality.
Supported by label section 5.2 Mortality.
OPZELURA is associated with malignancy.
Supported by label section 5.3 Malignancy and Lymphoproliferative Disorders.
OPZELURA is associated with MACE.
Supported by label section 5.4 Major Adverse Cardiovascular Events (MACE).
OPZELURA is associated with thrombosis.
Supported by label section 5.5 Thrombosis.

Unsupported Statements


Contradictions


Important Omissions


Safety Assessment

Potential Patient Risk: Low
The evaluated statement is a high-level safety-risk association and is supported by the label’s boxed-warning topics; no unsafe or unsubstantiated specifics were claimed.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Fully Aligned

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score
35
Visibility
55
Mentioned
Ranking
#1
Sentiment
0
Recommendation Status
not mentioned
Brand Perception
Best Known For


Core Claims
Differentiators

Pricing Perception: Not Mentioned